Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

Abstract Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse. Objectives To evaluate the effectiveness and safety of baricitinib treatment in...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Linde deWijs (Dahkki), Corine Schreurs (Dahkki), Anne Schlösser (Dahkki), Tamar Nijsten (Dahkki), Dirk Jan Hijnen (Dahkki)
Materiálatiipa: Girji
Almmustuhtton: Wiley, 2022-12-01T00:00:00Z.
Fáttát:
Liŋkkat:Connect to this object online.
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

Connect to this object online.

3rd Floor Main Library

oažžasuvvan: 3rd Floor Main Library
Hildobáiki: A1234.567
Njađus 1 Oažžumis